文献速递脑血管病

西洛他唑加用治疗颈动脉支架置入术后支架内再狭窄的随机对照试验

Randomized Controlled Trial of Cilostazol Addition for In-Stent Restenosis After Carotid Artery Stenting.
PubMed 文献 · Stroke · 2024-11-25

这项随机、开放标签、盲法终点试验纳入631例接受颈动脉支架置入术(CAS)的症状性或无症状性颈动脉狭窄患者,比较在其它抗血小板药基础上加用西洛他唑与不加用的效果。2年内支架内再狭窄(ISR)累积发生率西洛他唑组为10.8%,非西洛他唑组为19.6%(HR 0.64,95%CI 0.41-1.0,P=0.056)。作者认为加用西洛他唑可能有助于减少CAS患者慢性期ISR,但其真实性取决于足够统计学效能的进一步研究。

要点

  • 2年内ISR累积发生率西洛他唑组10.8% vs 非西洛他唑组19.6%,HR 0.64(95%CI 0.41-1.0),P=0.056。
  • 探索性分析中CAS后30天以后ISR发生率西洛他唑组10.3% vs 非西洛他唑组19.3%,P=0.040。
  • 心血管事件或任何死亡及出血事件两组相似(6.2% vs 6.7%;2.3% vs 1.4%)。

核心结论

  • 加用西洛他唑至其它抗血小板药可能有助于减少接受CAS患者慢性期的ISR,其真实性取决于足够统计学效能的进一步研究。

研究设计与样本

  • 随机、开放标签、盲法终点试验,纳入症状性和无症状性颈动脉狭窄并计划接受CAS的患者,随机分为在其它抗血小板药基础上加用西洛他唑(50或100 mg,每日两次,CAS前3天开始)或不加用西洛他唑,其它抗血小板药合用不受限制。
  • 计划样本量为900例(每组450例),最终631例(平均年龄69.9岁,558例男性,西洛他唑组325例,非西洛他唑组306例)纳入主要分析;招募时间为2010年12月至2015年9月。

主要发现

  • 2年随访内ISR在西洛他唑组325例中发生31例(累积发生率10.8%),非西洛他唑组306例中发生46例(19.6%)(风险比0.64[95%CI 0.41-1.0];P=0.056)。
  • 探索性分析中,CAS后30天以后ISR发生率西洛他唑组低于非西洛他唑组(10.3% vs 19.3%;P=0.040)。
  • 心血管事件或任何死亡及出血事件发生率两组相似(分别为6.2% vs 6.7%和2.3% vs 1.4%)。

关键数值与推荐

  • ISR通过双功能超声上收缩期峰值流速至少1.75 m/s诊断。
  • 主要结局为CAS后2年内ISR发生率;次要结局包括心血管事件或任何死亡以及出血事件的发生。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 样本量最初设定为900例(每组450例),但最终仅631例纳入主要分析。
  • 作者结论指出加用西洛他唑减少ISR的真实性取决于足够统计学效能的进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Restenosis after carotid artery stenting (CAS) is associated with the risk of developing ischemic stroke. We aimed to evaluate the inhibitory effect of cilostazol addition on in-stent restenosis (ISR) in patients treated with CAS. METHODS: In a randomized, open-label, blind-end point trial, patients with symptomatic and asymptomatic carotid artery stenosis and scheduled for CAS were randomly assigned to adding cilostazol (50 or 100 mg, twice per day) on other antiplatelets from 3 days before CAS or not adding cilostazol. Concomitant use of other antiplatelets was unrestricted. ISR was diagnosed by a peak systolic velocity of at least 1.75 m/s on duplex ultrasonography. The primary outcome was incidence of ISR within 2 years after CAS. Secondary outcomes included occurrences of cardiovascular events or any death and hemorrhagic events. RESULTS: Participants were recruited from December 2010 to September 2015. Although the sample size was initially set to be 900 (450 in each group), 631 patients (mean age 69.9 years, 558 men, 325 in the cilostazol, and 306 in the noncilostazol group) were included in the primary analysis. Within 2 years' follow-up, ISR occurred in 31 of 325 patients (cumulative incidence 10.8%) in the cilostazol group and 46 of 306 patients (19.6%) in the noncilostazol group (hazard ratio, 0.64 [95% CI, 0.41-1.0]; P=0.056). In the exploratory analysis, incidence of ISR beyond 30 days after CAS was lower in the cilostazol group than in the noncilostazol group (10.3% versus 19.3%; P=0.040). Incidences of cardiovascular events or any death and hemorrhagic events were similar between the groups (6.2% versus 6.7% and 2.3% versus 1.4%, respectively). CONCLUSIONS: The addition of cilostazol to other antiplatelet agents could contribute to the reduction of ISR in the chronic stage of patients who underwent CAS, the authenticity of which depends on further studies with sufficient statistical power. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01261234.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Yamagami H, Ozaki T, Ogasawara K, et al. Randomized Controlled Trial of Cilostazol Addition for In-Stent Restenosis After Carotid Artery Stenting. Stroke. 2024. PMID: 39585936. doi:10.1161/STROKEAHA.124.047210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。